Table 1.
Patient Characteristics of the study population
| Total (n = 857) | MVI (n = 327) | Non-MVI (n = 530) | P value | |
|---|---|---|---|---|
| Age (years), mean ± SD | 58.6 ± 11.5 | 58.9 ± 11.4 | 58.5 ± 11.6 | 0.645 |
| Male, n (%) | 670 (78.2) | 259 (79.2) | 411 (77.5) | 0.568 |
| Diabetes mellitus, n (%) | 222 (25.9) | 89 (27.2) | 133 (25.1) | 0.491 |
| HBV, n (%) | 484 (56.5) | 185 (56.5) | 299 (56.4) | 0.963 |
| HCV, n (%) | 300 (35.0) | 129 (39.4) | 171 (32.3) | 0.032 |
| AST > 40 U/L, n (%) | 321 (37.5) | 119 (36.4) | 202 (38.1) | 0.613 |
| ALT > 40 U/L, n (%) | 374 (43.6) | 139 (42.5) | 235 (44.3) | 0.599 |
| Platelets < 150 103/µL, n (%) | 411 (48.0) | 171 (52.3) | 240 (45.3) | 0.046 |
| Albumin (g/dL); mean ± SD | 3.6 ± 0.6 | 3.6 ± 0.6 | 3.7 ± 0.6 | 0.129 |
| Liver cirrhosis, n (%) | 400 (46.7) | 157 (48.0) | 243 (45.8) | 0.537 |
| Child-Pugh grade, n (%) | 0.216 | |||
| A | 786 (91.7) | 295 (90.2) | 491 (92.6) | |
| B | 71 (8.3) | 32 (9.8) | 39 (7.4) | |
| BCLC stage, n (%) | < 0.001 | |||
| 0 | 124 (14.5) | 6 (1.8) | 118 (22.3) | |
| A | 733 (85.5) | 321 (98.2) | 412 (77.7) | |
| AFP > 10 ng/mL, n (%) | 446 (52.5) | 198 (60.6) | 248 (46.8) | < 0.001 |
| Tumor size (cm)a; mean ± SD | 2.9 ± 1.0 | 3.0 ± 1.0 | 2.8 ± 1.0 | < 0.001 |
| Tumor number, n (%) | 0.186 | |||
| Single | 780 (91.0) | 303 (92.7) | 477 (90.0) | |
| Multiple | 77 (9.0) | 24 (7.3) | 53 (10.0) | |
| Histological grade n (%) | < 0.001 | |||
| Well | 111 (13.1) | 13 (4.0) | 98 (18.8) | |
| Moderate | 715 (84.3) | 302 (92.6) | 413 (79.1) | |
| Poor | 22 (2.6) | 11 (3.4) | 11 (2.1) | |
| Capsule invasionb, n (%) | 738 (86.3) | 283 (86.5) | 455 (86.2) | 0.878 |
| Satellite nodule, n (%) | 21 (2.5) | 19 (5.8) | 2 (0.4) | < 0.001 |
| MAFLD, n (%) | 105 (23.3) | 43 (22.1) | 62 (24.2) | 0.589 |
Data are expressed as mean ± standard deviation or n (%). Abbreviations: MVI, microvascular invasion; CHB, chronic hepatitis B; CHC, chronic hepatitis C; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha fetoprotein; BCLC, Barcelona clinical liver cancer; MAFLD, metabolic-associated fatty liver disease.
a
Diameter of the largest tumor nodule.
b
Including partial and totally capsule invasion, and no well capsule.